Larvol Veri

BIOMARKER:

STAG2 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

STAG2 mutation STAG2 mutation	Acute Myelogenous Leukemia AML	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
STAG2 mutation STAG2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine/daunorubicin liposomal formulation Sensitive : C3
STAG2 mutation STAG2 mutation	Acute Myelogenous Leukemia AML	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
STAG2 mutation STAG2 mutation	Colorectal Cancer CRC	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
STAG2 mutation STAG2 mutation	Glioblastoma GBM	olaparib Sensitive: D – Preclinical olaparib Sensitive : D